
Ryvu Therapeutics S.A.
Research and experimental development in natural sciences and engineering
Overview
RYVU Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule therapies for precision oncology. Its pipeline includes RVU305 for MTAP-deleted tumors, romaciclib (RVU120) for R/R AML, myelofibrosis and LR-MDS, and dapolsertib for DLBCL. The company runs clinical studies and advances programs in kinase, synthetic lethality, and immuno-oncology pathways.
Financials
Revenue history (in m)
Filing timeliness
Financial statements were filed on time, on average 10 days early. All were audited by a statutory auditor.
- 202530/06/2026
- 202401/07/2025
- 202309/07/2024
- 202207/07/2023
- 202114/07/2022
- 202029/09/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 17.50
- High
- PLN 17.50
- Low
- PLN 16.90
- Volume
- 11.6K
- Avg. vol.
- 15.47K
- Market cap
- PLN 393.04M
- P/E ratio
- –
- EPS
- -PLN 2.94
- Shares outstanding
- 23.12M
- 52-week
- PLN 16.00 – 18.14
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLSELVT00013
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 3.24m | USD -4.52m | USD -3.53m |
| Q1 2026 | USD 4.58m | USD -3.35m | USD -3.42m |
| Q4 2025 | USD 4.52m | USD -4.22m | USD -4.42m |
| Q3 2025 | USD 3.75m | USD -6.38m | USD -6.20m |
Results for Q3 2026:Nov 19, 2026
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Public procurement
3 tenders recorded as contractor: 2 national ($3,202) and 1 EU ($468,067).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Aug 25, 2026 | ZP/CZD/062/26 Supply of the investigational medicinal product romaciclib (RVU 120) for use in the non-commercial MEDWAY clinical trial “Phase I study of the use of the CDK8 inhibitor RVU120 in combination with everolimus in children with relapsed or progressive group 3 or 4 medulloblastoma” | $468.1K$468,067 | Instytut Pomnik - Centrum Zdrowia Dziecka | |
| Nov 20, 2024 | Syllabus consultations to modify the first- and second-cycle Biology programmes and the second-cycle Natural Resources Management programme – “Key to the future-Kompleksowy program rozwoju kształcenia na potrzeby branż kluczowych UJ-22 cz.” | $3,017$3,017 | Uniwersytet Jagielloński | |
| Oct 29, 2024 | Syllabus consultations to modify the first- and second-cycle Biology programmes and the second-cycle Natural Resources Management programme – “Key to the future-Kompleksowy program rozwoju kształcenia na potrzeby branż kluczowych UJ-22 cz.” | $185$185 | Uniwersytet Jagielloński |
Authorized Representatives
Manner of representation
In the case of a multi-member management board, two members of the management board acting jointly, or a member of the management board acting jointly with one of the joint commercial proxies, are authorized to represent the company.
Supervisory board
Beneficial owners
Ryvu Therapeutics is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.
Bank accounts
Registered as a VAT taxpayer on 2007-08-10.
82 1240 4432 1111 0010 6455 3837
40 1280 0003 0000 0031 8529 5031
27 1240 2294 1978 0010 7348 1703
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jun 13, 2011 | Shareholders' meeting convened |
Public aid
53 public aid cases recorded, with a total value of $86,209,007.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 10, 2026 | Aid for research and development projects: industrial research | $3.1M$3,064,666 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Mar 10, 2026 | Aid for research and development projects: experimental development | $2.3M$2,326,177 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Apr 22, 2025 | Aid for research and development projects: industrial research | $2.5M$2,480,957 | Prezes Agencji Badań Medycznych |
European Funds
4 projects recorded: 3 from FE lists ($14,123,711) and 1 Commission grant (FTS) ($0).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-10-01 | PERO – Predictive Engineering for Rational Oncology: functional mapping of therapeutic targets in oncology. | $5M$5,011,779 | European Funds for a Modern Economy | |
| 2023-05-01 | ONCO Prime: new possibilities for personalized cancer therapy based on primary cell culture from patients, omics characterization and functional testing. | $6.3M$6,268,132 | European Funds for a Modern Economy | |
| 2018-12-02 | A new targeted therapy for cancers with MTAP gene deletion – phase II. | $2.8M$2,843,801 | European Funds for a Modern Economy |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| Waste generation | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Selvita S.A. | $91,692,114.52 | selvita.com | ||
| Sieć Badawcza Łukasiewicz - Port Polski Ośrodek Rozwoju Technologii Research institute | $24,232,583.73 | port.lukasiewicz.gov.pl | ||
| Ardigen S.A. | $12,513,309.89 | ardigen.com | ||
| Jagiellońskie Centrum Innowacji sp. z o.o. | $10,019,041.09 | jagiellonskiecentruminnowacji.pl | ||
| Kapadi sp. z o.o. | $7,248,714.39 | kapadi.com | ||
| Farmepo sp. z o.o. | $5,296,484.28 | farmepo.com | ||
| JJP Biologics sp. z o.o. | $4,998,735.31 | jjpbiologics.com | ||
| Proacta S.A. | $3,747,821.54 | proacta.pl | ||
| Aronpharma sp. z o.o. | $3,197,864.33 | aronpharma.pl | ||
| Poltreg S.A. | $2,701,406.33 | poltreg.com |
Change history
| Date | Event | |
|---|---|---|
| 2023-01-17 | Share capital increase (7,342,189.60 PLN → 9,248,059.20 PLN) | |
| 2020-10-09 | Address change (Bobrzyńskiego 14, 30-348, Kraków → Ul. Leona Henryka Sternbacha 2, 30-394, Kraków) | |
| 2020-08-18 | Share capital increase (6,388,491.60 PLN → 7,342,189.60 PLN) | |
| 2019-10-01 | Name change (Selvita → Ryvu Therapeutics) | |
| 2018-03-16 | Share capital increase (5,508,491.60 PLN → 6,388,491.60 PLN) |
FAQ
Last updated: 2026-10-07